Clinical features and prognosis of pediatric acute megakaryocytic leukemia.
- Author:
Tie-Mei LUO
1
;
Jie YU
1
;
Xi-Zhou AN
1
Author Information
1. Department of Hematology and Oncology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 401122, China.
- Publication Type:Journal Article
- MeSH:
Child;
Disease-Free Survival;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Megakaryoblastic, Acute/therapy*;
Neoplasm, Residual;
Prognosis;
Remission Induction;
Survival Rate;
Treatment Outcome
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(6):613-620
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical features and prognosis of children with acute megakaryocytic leukemia (AMKL) and the clinical effect of acute myeloid leukemia 03 (AML03) regimen for the treatment of pediatric AMKL.
METHODS:The clinical data were collected from 47 children with AMKL who were diagnosed from May 2011 to December 2019. The treatment outcomes and prognostic factors were analyzed. The Kaplan-Meier method and the log-rank test were used for survival analysis.
RESULTS:Among the 47 children with AMKL, 22 with non-Down syndrome-AMKL were treated by the AML03 regimen, with a median follow-up time of 11.4 months. For the 22 non-Down syndrome-AMKL patients, the remission rate of bone marrow cytology was 85% and the negative rate of minimal residual disease (MRD) was 79% after induction Ⅱ, with a 2-year overall survival (OS) rate of (50±13)% and a 2-year event-free survival (EFS) rate of (40±12)%. The group with positive immunophenotypic marker CD56 had significantly lower 2-year EFS and OS rates than the group with negative CD56 (
CONCLUSIONS:Children with AMKL tend to have a low remission rate and a poor prognosis. Positive immunophenotypic marker CD56, bone marrow cytology during early treatment response, and MRD results are important factors influencing the prognosis. Allogeneic hematopoietic stem cell transplantation has no significant effect on the prognosis of AMKL.
